Cy­toIm­mune CEO breaks down her 3 'pil­lars' of suc­cess; For­mer No­var­tis, Gilead ex­ec Alessan­dro Ri­va to lead an ul­tra low-pro­file cell ther­a­py out­fit

Christi­na Cough­lin loves cell ther­a­py — pret­ty much defin­ing her ca­reer since her post­doc days with Carl June in Penn­syl­va­nia.

Now as the new head hon­cho at Cy­toIm­mune as of Wednes­day, the first-time CEO gets to work with a new type of cell ther­a­py — CAR-NK cells, li­censed from long-time NK cell re­searcher Michael Caligiuri and Jian­hua Yu at the City of Hope Na­tion­al Med­ical Cen­ter.

And Yu is the sole mem­ber of Cy­toIm­mune’s sci­en­tif­ic ad­vi­so­ry board.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.